Advertisement
CLLS vs TGTX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLLS is a Hold and TGTX is a Hold.
Momentum Indicator for CLLS turns negative, indicating new downward trend
CLLS saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned negative. In 83 of the 87 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for CLLS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for CLLS just turned positive on October 05, 2026. Looking at past instances where CLLS's MACD turned positive, the stock continued to rise in 38 of 46 cases over the following month. The odds of a continued upward trend are 83%.
Following a +3.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLLS advanced for three days, in 174 of 219 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
CLLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.391) is normal, around the industry mean (2.973). P/E Ratio (-1.523) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (2.441) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. CLLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for TGTX turns negative, indicating new downward trend
TGTX saw its Momentum Indicator move below the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 70 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for TGTX turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 34 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
TGTX moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TGTX crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TGTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 64 cases where TGTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
Following a +3.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where TGTX advanced for three days, in 254 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
TGTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 179 of 210 cases where TGTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. TGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.470) is normal, around the industry mean (2.973). P/E Ratio (17.373) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (11.136) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
CLLS | TGTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 70 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 59 Fair valued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 60 | |
SMR RATING 1..100 | 98 | 14 | |
PRICE GROWTH RATING 1..100 | 94 | 42 | |
P/E GROWTH RATING 1..100 | 8 | 96 | |
SEASONALITY SCORE 1..100 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CLLS's Valuation (59) in the Biotechnology industry is in the same range as TGTX (90). This means that CLLS’s stock grew similarly to TGTX’s over the last 12 months.
TGTX's Profit vs Risk Rating (60) in the Biotechnology industry is somewhat better than the same rating for CLLS (100). This means that TGTX’s stock grew somewhat faster than CLLS’s over the last 12 months.
TGTX's SMR Rating (14) in the Biotechnology industry is significantly better than the same rating for CLLS (98). This means that TGTX’s stock grew significantly faster than CLLS’s over the last 12 months.
TGTX's Price Growth Rating (42) in the Biotechnology industry is somewhat better than the same rating for CLLS (94). This means that TGTX’s stock grew somewhat faster than CLLS’s over the last 12 months.
CLLS's P/E Growth Rating (8) in the Biotechnology industry is significantly better than the same rating for TGTX (96). This means that CLLS’s stock grew significantly faster than TGTX’s over the last 12 months.
| CLLS | TGTX | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| MACD ODDS (%) | 1 day ago 83% | 1 day ago 79% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 80% |
| Advances ODDS (%) | 25 days ago 79% | 8 days ago 84% |
| Declines ODDS (%) | 4 days ago 89% | 1 day ago 83% |
| BollingerBands ODDS (%) | 1 day ago 86% | 1 day ago 86% |
| Aroon ODDS (%) | 1 day ago 84% | 1 day ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLLS’s FA Score shows that 1 FA rating(s) are green while TGTX’s FA Score has 1 green FA rating(s).
- CLLS’s FA Score: 1 green, 4 red.
- TGTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLLS’s TA Score shows that 4 TA indicator(s) are bullish while TGTX’s TA Score has 4 bullish TA indicator(s).
- CLLS’s TA Score: 4 bullish, 3 bearish.
- TGTX’s TA Score: 4 bullish, 5 bearish.
Price Growth
CLLS (@Biotechnology) experienced а -11.76% price change this week, while TGTX (@Biotechnology) price change was -5.07% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
CLLS is expected to report earnings on Nov 06, 2026.
TGTX is expected to report earnings on Nov 02, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CLLS and
Correlation & Price change
A.I.dvisor indicates that over the last year, CLLS has been loosely correlated with SLN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CLLS jumps, then SLN could also see price increases.
| Ticker / NAME | Correlation To CLLS | 1D Price Change % | ||
|---|---|---|---|---|
| CLLS | 100% | +0.67% | ||
| SLN - CLLS | 43% Loosely correlated | -0.05% | ||
| MDGL - CLLS | 40% Loosely correlated | -1.01% | ||
| PMVP - CLLS | 38% Loosely correlated | -4.04% | ||
| AXON - CLLS | 36% Loosely correlated | +2.98% | ||
| TGTX - CLLS | 36% Loosely correlated | -0.08% | ||
More | ||||
TGTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, TGTX has been loosely correlated with ARQT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if TGTX jumps, then ARQT could also see price increases.
| Ticker / NAME | Correlation To TGTX | 1D Price Change % | ||
|---|---|---|---|---|
| TGTX | 100% | -0.08% | ||
| ARQT - TGTX | 39% Loosely correlated | +1.04% | ||
| PTGX - TGTX | 38% Loosely correlated | +1.05% | ||
| KRYS - TGTX | 37% Loosely correlated | -0.63% | ||
| ARRY - TGTX | 36% Loosely correlated | -3.23% | ||
| PTCT - TGTX | 36% Loosely correlated | +0.67% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BTO | 37.37 | 0.72 | +1.96% |
| John Hancock Financial Opportunities Fund | |||
| UPSX | 9.07 | 0.12 | +1.34% |
| Tradr 2X Long UPST Daily ETF (UPSX) | |||
| HTAB | 18.33 | 0.17 | +0.94% |
| Hartford Schroders Tax-Aware Bond ETF (HTAB) | |||
| KDEC | 28.11 | 0.01 | +0.03% |
| Innovator U.S. Small Cap Power Buffer ETF - December (KDEC) | |||
| VOT | 289.24 | -4.59 | -1.56% |
| Vanguard Morningstar Mid-Cap Growth ETF (VOT) | |||